The monoclonal antibody bevacizumab that inhibits the growth of tumor blood vessels by binding to VEGF (vascular endothelial growth factor) prolongs overall survival by 4 months but only in recurrent, not in primary glioblastoma [13]. This evidence concerns the gene VEGFA and glioblastoma.